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Abstract 
Background: Premenstrual syndrome (PMS) is a disorder characterized by Physical and psychological symptoms and 
often occur between 10 to 14 days prior to menstruation and end shortly after the onset of menstruation. It can negatively 
affect women’s daily activities. Recent studies demonstrate that calcium and vitamin B1 can reduce the symptoms of 
PMS. The aim of this study was to compare the effect of calcium, vitamin B1 and placebo on treatment of PMS in 
students residing at dormitories of Ilam University of Medical Sciences in 2016. 
Materials and Methods: In this four-blind placebo-controlled clinical trial, 264 students with PMS residing at 
dormitories of Ilam University of Medical Sciences were divided randomly into four groups, 1) received vitamin B1, 2) 
received calcium, 3) received vitamin B1 plus calcium and 4) received placebo. All samples took pills once daily for 2 
successive menstrual cycles and completed the questionnaires. The data were analyzed using descriptive statistics, Paired 
t-test and the independent t-test. 
Results: Our results showed that after treatment, severity of PMS symptoms reduced significantly in all groups 
(p<0.001). However, comparison of the severity of PMS symptoms between intervention groups and the placebo group 
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after intervention revealed that, there was a significant difference in this respect (P < 0. 001). Furthermore, mean 
reduction of PMS symptoms in Vitamin B1 plus calcium group was more than other groups. 
Conclusion: According to our findings, treatment with vitamin B1 or calcium reduces the severity PMS symptoms but 
concurrent use of both vitamin B1 plus calcium is more effective in reducing PMS symptoms. Therefore, this treatment 
can be used to reach a major goal of midwifery, by decreasing the severity of PMS symptom. 
Key Words: premenstrual syndrome, Thiamine (B1),   Calcium Carbonate, female. 
Introduction: 
Every woman has menstruation for about 30 to 35 years in her life.  Premenstrual disorders (PMS) are characterized by a 
variety of unpleasant somatic and psychological symptoms of varying severity that occur regularly during the luteal phase 
of the menstrual cycle and resolve during menses and may affect the  quality of life (1-4). 
The prevalence of PMS in the reproductive age has been estimated to be between10%–90% in relation to the studied 
population and the type of assessment tool used(5, 6)PMS may be influenced by some factors like age, menstrual cycle 
characteristics, socioeconomic and educational levels, use of hormonal contraceptives, and lifestyle including diet, habits, 
and physical activities (7, 8) 
A total of 150 PMS symptoms have been identified that the most frequent symptoms include breast tenderness, headache, 
stomachache, back pain, mood swings, tearfulness, anger, confusion, sleep disorder, social withdrawal, fatigue, 
clumsiness, tension, anxiety, irritability, depression, food craving, constipation and changes in sexual sensation(9-11). 
PMS can even cause more serious problems such as marital relation disruption, mother-child problems, social isolation, 
decreased attention, increased psychosomatic symptoms, and even suicide and legal problems(8).    
Approximately, 85-90% of women experience various degrees of these symptoms in reproductive age(8).   This syndrome 
affects women in all countries where PMS has been investigated(12).  
Because of the direct costs for the healthcare system and especially the indirect costs through the loss of work 
productivity, effective treatment is needed(13). The suggested treatments are as follows: pharmacological therapies (such 
as, antidepressants, anxiolytics, cycle-modifying hormonal agents), nutritional supplements (such as, bromocriptine, 
vitamin D, calcium, magnesium), natural products (such as, vitexagnuscastus extract, evening primrose oil), lifestyle 
changes (such as, exercise, following dietary recommendations, relaxation therapy) and cognitive behavioral therapy (14). 
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Vitamin B1(Thiamin) is one of the complementary therapies used to treat the PMS. It can be effective in treatment of 
PMS symptoms such as nausea and vomiting. It can also increase the quality of life and decrease depression, fatigue, 
dysmenorrhea, muscle cramps, and anxiety through coenzyme functions in the metabolism of carbohydrates and main 
branch of amino acid that plays an important role in appearance of physical and mental symptoms of PMS (15). 
Calcium is one of the other nutritional supplements used to treat the PMS. It may play role in the physical and 
psychological aspect of PMS(16).   Changes in calcium concentration could have stimulatory effects on neuromuscular 
junctions, irritability, fatigue, anxiety, mood changes, change in appetite, depression and muscle cramps(17). Some 
studies also revealed that in women with PMS, the levels of calcium and some trace elements in red blood cells were 
lower than normal women(16).  
Previous studies investigated the role of each of these drugs in treatment of PMS; However, regarding the high prevalence 
of PMS and lack of definitive treatment in this regard in Iran we conducted this study to compare the effect of calcium, 
vitamin B1, calcium plus vitamin B1 and placebo on treatment of the PMS symptoms in students residing at dormitories of 
Ilam University of Medical Sciences in 2016. 
Materials and Methods: 
This randomized, four-blind clinical trial was performed on students residing at dormitories of Ilam University of Medical 
Sciences. The study was confirmed by Ethics Committee of Ilam University of Medical Sciences on 12/09/2015 and was 
awarded the permission number of ir.medilam.rec.1394.88  and The registered number in Iranian registry of clinical trial 
is IRCT2016011810333N3. All information about participants was preserved and the results were reported anonymously. 
All performed tests and services in the study were free and patients were not charged for any of them. After providing the 
necessary clarifications about this study, all participants were asked to sign the written consent. 
The inclusion criteria were the as follows: 18 to 30 years old, having normal BMI, having regular menstrual cycles (3 to 8 
days of menstruation between 22 to 35 days), not taking medications such as antidepressants, hormones, contraceptives, 
vitamins, and herbal medications, not having mental or physical disorder including depressive disorders, anxiety and 
panic disorders, migraine headache, irritable bowel syndrome, asthma, chronic fatigue syndrome, thyroid and adrenal 
disorders and disorders included in the differential diagnosis of PMS, not having contraindications to take supplements 
containing calcium Carbonate or vitamin B and  not to undergo surgical operation. The students who had the inclusion 
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criteria were given the PMS diagnosis questionnaire. They recorded their symptoms on PMS diagnosis questionnaire to 
confirm having PMS. This questionnaire is taken from study of Bakhshani et al (18).It has been designed with the help of 
DSM-IV definition of PMDD and existing literature on PMS. The questionnaire consisted two sections: The first part 
included socio-demographic questions such as age, marital status, and residency condition and the second part included 
21 self-reporting items assessing frequency and severity of PMS. The questions on the form addressed the most prevalent 
symptoms including 11 of psychiatric symptoms and 10 of physical symptoms. The participants were asked to identify 
symptoms they had experienced during two weeks preceding their menstruation in the past two months. Those who had 
experienced at least 5 symptoms 7 days before menstruation up to 4 days after menstruation were diagnosed to have PMS.  
The total sample size is set to N = 500 according to similar studies  (19) by considering α = 0.05, power 80%,  308 out of 
the first five hundred students who filled out PMS diagnosis questionnaire, had mild to moderate PMS and were asked to 
take part in this study, 44 students were reluctant to participate in  the study and therefore were excluded, remaining a 
total of 264 students. Then, they were randomly divided into four groups. There were 66 students in each group. Students 
in the first group received tablets containing 100 mg of vitamin B1 (vitamin B1 tablets were produced by the 
pharmaceutical company of Tehran Chimi, Iran); those in the second group received tablets containing 500 mg of calcium 
carbonate (calcium were produced by the pharmaceutical company of Tehran Chimi, Iran). Those in the third group 
received tablets containing 100 mg of vitamin B1and 500 mg of calcium carbonate and those in the fourth group received 
a placebo. tablets containing placebo were made by 1(gr) food starch. All tablets were given to the participants while they 
were unaware of the content of the tablets. All participants took tablets once daily during one week before menstruation to 
4 days after menstruation for the 2 successive cycles and, concurrently, completed the questionnaires to evaluate changes 
in the intensity of their symptoms. The questionnaires were collected at the end of 2 cycles and data were analyzed using 
SPSS16 software. We used the Paired t-test to compare changes in the severity of PMS symptoms in each group before 
and after the intervention and the independent t-test was used to compare changes in the severity of PMS symptoms 
between groups.  P < 0.05 was considered statically significant. 
Results: 
264 out of 308 students screened primarily and had moderate and sever form of PMS were divided into four groups, 66 
students received vitamin B1, 66 students received calcium carbonate, 66 students received vitamin B1plus calcium 
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carbonate and 66 students received placebo. Twenty-five participants dropped out during the two month of the 
intervention. Therefore, the final analysis was performed on 239 samples (Figure 1). 
The mean age of participants was 20.32± 8.92 years (range, 18–25 years), BMI was 22.1± 8.92, the mean number of days 
of the menstrual cycle was 28.41± 3.04 and the mean number of days in period was 6.38± 3.05. Majority of participants 
were single (89.53%). All participants had similar Socio- demographic and psychometric status. 
Before treatment, the symptoms of PMS were mainly in the severe range in each group. As it is shown before the 
treatment, there was no difference in symptoms between groups and all groups were matched in this regard (Table 1). The 
average severity of symptoms in each group was compared to placebo group before the treatment, and their homogeneity 
was proved. According to the results of independent t-test, before the treatment, there was no significant difference in 
PMS symptoms between placebo group and other groups  ) P ˃0.05)(Table 2). Table 1 presents the average severity of 
PMS symptoms before and after intervention in each group. There was a significant difference between the average 
severity of PMS of symptoms before and after intervention in each group (P<0.05). In all groups, the severity of PMS 
symptoms reduced significantly after treatment (p<.001). However, the symptoms of PMS were mainly moderate in 
vitamin B1, calcium carbonate and vitamin B1 plus calcium groups after treatment; but the symptoms were still in the 
severe range in the placebo group. 
1. Table1.The comparison of the PMS symptoms before and after intervention. 
 
 
 
 
 
 
 
 
 
 
a
Values are given as mean±SD, statistical significance assessed using the Paired t-test. 
Groups  Before 
intervention 
After 
intervention 
Difference of 
means 
P-value 
Groups  Before 
intervention 
After 
intervention 
Difference of 
means 
P-value 
Vitamin B1 61.22±30.51 45.91±13.36 19.63±21.82 <0.001 
Calcium 61.2±31.4 39.9±11.14 31.89±20.11 <0.001 
Vitamin B1 plus 
Calcium 
62.04±30.53 25.31±16.83 41.72±23.81 <0.001 
Placebo 61.02±30.52 53.91±18.31 11.52±30.61 <0.001 
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Table2. The comparison of symptoms of PMS between three groups and the placebo group 
Symptoms of PMS Groups P-value 
Vitamin B1 Placebo  
Before treatment 61.22±30.51 61.02±30.52 ˃0.05 
After treatment 45.91±13.36 53.91±18.31 <0.001 
 Calcium Placebo  
Before treatment 61.2±31.4 61.02±30.52 ˃0.05 
After treatment 39.9±11.14 53.91±18.31 <0.001 
 Vitamin B1 plus Calcium Placebo  
Before treatment 62.04±30.53 61.02±30.52 ˃0.05 
After treatment 25.31±16.83 53.91±18.31 <0.001 
Data are presented as mean±SD, statistical significance assessed using the Independent t-test. 
Effect of treatments on the average of severity of PMS symptoms is shown in Table 2. The average of symptoms severity 
in each group was compared to placebo group after intervention, and their homogeneity was proved. Our results showed 
that, there was a significant difference between the average PMS symptoms in vitamin B1 and the placebo group after 
intervention. Vitamin B1 decreased the symptoms significantly more than placebo (P < 0.0001). 
there was a significant difference between calcium group and the placebo group in comparison of the average PMS 
symptoms after intervention revealed in this case (P< 0.0001). Furthermore, Calcium decreased the symptoms more than 
vitamin B1. A significant difference was also observed in symptoms of PMS between vitamin B1 plus calcium group and 
the placebo group after intervention (P < 0.0001). It was observed that the mean reduction of symptoms of PMS in 
Vitamin B1 plus calcium group was more than other groups (Table 1). The mean reduction of symptoms of PMS in 
groups was as follows: 
Vitamin B1 plus calcium ˃Calcium ˃Vitamin B1˃Placebo 
 
Figure-I. 
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 Discussions:                                                           
Premenstrual syndrome is one of the most prevalent causes of women's referral to physicians. In the present study, we 
compared the effect of calcium and vitamin B1 on treatment of the PMS symptoms. The reasons for using vitamin B1 and 
Calcium in our study were the efficiency, safety and inexpensiveness of these products. We developed a standardized 
intervention which all participants had to pass through. However, they differed in the severity of PMS symptoms and their 
need for treatment (20).To our knowledge, a standardized approach for treating PMS does not yet exist. According to 
what was said, our aim is now to find one effective intervention on treatment of the PMS symptoms. According to the 
survey of the existing literature on the effect of treatment with supplements in reducing symptoms of premenstrual 
syndrome, it should be mentioned that there are many confounding variables that can affect the findings. These variables 
include age, education, socioeconomic status, place of residence and the amount of stress. We minimized the influence of 
these variables by conducting a randomized, four -blind study among dormitory residents (all participants were matched 
according to the age, education, living place and life style); removing students using daily nutritional supplements and 
having a courier to hand over the packaged pills to the participants. Benefits and limitations of this study were discussed 
above.                                                                                                                                                                                          
Our results showed that before intervention, the severity of the PMS symptoms was clinically similar in all groups, and all 
were in the severe to moderate range (Table 1). At the end of intervention, the comparison of variations in severity of 
symptoms before and after intervention revealed that, the average of symptoms of PMS decreased significantly in all 
groups (P<0.05). However, there was a significant difference in severity of PMS symptoms between each intervention 
group and the placebo group after intervention (P < 0. 001). Therefore, vitamin B1, calcium and vitamin B1 plus calcium 
were more effective than placebo. Furthermore, vitamin B1B 1 plus calcium was more effective than other supplements in 
reducing symptoms of PMS. To our knowledge, this was the first study to examine the effect of calcium plus vitamin B1in 
the treatment of PMS symptoms. Therefore, comparing results of this study with those of other studies was limited. 
Results of Khajehei et al.’s study (17) also showed that simultaneous consumption of calcium and vitamin D was more 
effective than placebo (P<0.05). Our results confirm those of previous studies regarding the positive effect of vitamin B1 
supplementation on premenstrual symptoms. The results of Abdollahifard et al.’s study showed that vitamin B1 reduces 
mental, physical and overall severity of symptoms of PMS (15). The result of Zafari et al is consists with our study too  
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(21).In the prospective study, Bertone-Johnson (22)et al found that high intakes of vitamin B1 from food sources were 
associated with a significantly lower incidence of PMS. Some of other studies showed that vitamin B1 was effective in 
increasing the quality of life; releasing energy, reducing skeletal muscle cramps, promoting perfusion to the heart, 
kidneys, liver, and brain, improving digestion and metabolism of carbohydrates and aminoacids and consequently, 
decreasing physical and psychological symptoms of PMS such as pain, fatigue, depression, stress, anxiety, and sleep 
disorders(23-25)   
Vitamin B1 (thiamine) acts as a coenzyme and reduces symptoms of PMS through affecting the performance of 
coenzymes in the metabolism of carbohydrates, lipids, protein and main branch of amino acid that plays an important role 
in appearance of physical and psychological symptoms of PMS(15, 26)  It affects the function of cardiovascular system, 
the urinary tract, blood circulation, neurological system. It is also effective in treatment of psychological symptoms of 
PMS such as depression, fatigue, and anxiety through affecting the brain, increasing endorphin secretion and subsequently 
causing relaxation and stimulating sleeping(15).  Our results also confirm those of previous studies regarding the positive 
effect of calcium supplementation on premenstrual symptoms. Thys-Jacobs et al. (27) conducted a double-blind clinical 
trial involving 466 women diagnosed with moderate to severe PMS. In this study, improvements in physical and 
psychological symptoms were observed in 48% of women who used calcium supplements, compared with only 30% in 
the placebo group (P < .001). Some studies confirmed that intake of calcium carbonate was associated with reduction in 
symptoms of PMS(24, 25, 27). Penland and Johnson (28) showed that calcium supplements decreased psychological 
symptoms related to PMS (p < 0.01). Ghanbari et al.’s study(16) revealed that PMS symptoms such as early tiredness, 
appetite changes and depression were reduced significantly more in the women receiving calcium than in those receiving 
placebo too. Changes in intracellular and extracellular calcium concentration could have stimulatory affect the 
neuromuscular junctions and psychological symptoms of PMS(29, 30) .The study by Akhlaghi et al. (31) showed a 62% 
reduction in psychological symptoms and 61% reduction in physical symptoms after treatment with calcium. Shamberger 
revealed that in women with PMS, levels of calcium in red blood cells were lower than normal (32).   
In our study, a high proportion of women responded to placebo, which makes it difficult to establish the actual efficacy of 
any active treatment. This problem has been observed in other similar studies(29, 33).  It appears that receiving attention 
could positively affect the mental status of participants and cause the treatment of premenstrual syndrome.  In this study, 
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there were no statistically significant differences between groups regarding reported adverse effects. This study, suggests 
that treatment with calcium, vitamin B1, especially vitamin B1 plus calcium is a safe, inexpensive, effective and 
convenient method for reducing the intensity and frequency of PMS symptoms. With these drugs a lot of physical 
problems, stress and behavior conflict in everyday life can be prevented. Due to the importance of PMS in the overall 
quality of life of women, this result can be considered important. Given the study methodology, large sample size, and the 
treatment effect, these findings provide good evidence about the effectiveness of calcium, vitamin B1 and especially 
vitamin B1 plus calcium as a treatment for PMS. Therefore, it is recommended to be used as first-line treatment for PMS. 
Conclusion 
This study, which was performed for the first time in Iran, revealed that using vitamin B1 plus calcium in luteal phase 
could reduce overall severity of PMS symptoms needless of using it in the entire menstrual cycle. Additional studies are 
recommended to confirm these findings and to obtain enough evidence for treatment with vitamin B1 plus calcium as a 
safe and effective medication for patients who do not desire to or cannot undergo other treatments.  
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